Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 4/20 | 0.44 |
| ▸ | CCND1 | P24385 | 4/20 | 0.44 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.44 |
| ▸ | CDK2 | P24941 | 3/20 | 0.44 |
| ▸ | CCND2 | P30279 | 2/20 | 0.43 |
| ▸ | CCND3 | P30281 | 2/20 | 0.43 |
| ▸ | CSF1R | P07333 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 15/20 | 0.43 |
| ▸ | FGFR4 | P22455 | 8/20 | 0.43 |
| ▸ | FGFR2 | P21802 | 7/20 | 0.43 |
| ▸ | FGFR3 | P22607 | 7/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 6/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 5/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 3/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6073945 | 1.00 | CDK4 (0.44) | CDK4CCND1CCNA2CDK2CCND2 | |
| SCHEMBL6073724 | 0.91 | FGFR1 (0.44) | CDK4CCND1CCNA2CDK2CCND2 | |
| SCHEMBL6073620 | 0.91 | CDK4 (0.47) | CDK4CCND1CCNA2CDK2CCND2 | |
| SCHEMBL6073616 | 0.91 | CDK4 (0.47) | CDK4CCND1CCNA2CDK2CCND2 | |
| SCHEMBL6073732 | 0.91 | FGFR1 (0.44) | CDK4CCND1CCNA2CDK2CCND2 | |
| SCHEMBL6073930 | 0.90 | FGFR1 (0.48) | CDK4CCND1CCNA2CDK2CCND2 | |
| SCHEMBL6073925 | 0.90 | FGFR1 (0.48) | CDK4CCND1CCNA2CDK2CCND2 | |
| SCHEMBL6073429 | 0.89 | FGFR1 (0.47) | CDK4CCND1CCNA2CDK2CCND2 | |
| SCHEMBL6073424 | 0.89 | FGFR1 (0.47) | CDK4CCND1CCNA2CDK2CCND2 | |
| SCHEMBL6073723 | 0.86 | CDK4 (0.49) | CDK4CCND1CCNA2CDK2CCND2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030073668-A1 | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors | BOOTH RICHARD JOHN (US) | 2003-04-17 | — | — | US | claimed |
| US-7053070-B2 | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2006-05-30 | — | — | US | disclosed |
| US-20030073668-A1 | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors | BOOTH RICHARD JOHN (US) | 2003-04-17 | — | — | US | disclosed |
| EP-1254137-A1 | PYRIDO 2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2002-11-06 | — | — | EP | disclosed |
| WO-2001055147-A1 | PYRIDO[2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073668-A1 | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors | CDK9, CDK19, CDK3 | CDK4 19/4885CCND1 79/4885CCNA2 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.